RENNOVA HEALTH WELCOMES NEW CHIEF FINANCIAL OFFICER
WEST PALM BEACH, Fla, April 09, 2019 (GLOBE NEWSWIRE) — Rennova Health, Inc. (OTC: RNVA), (OTC: RNVAW), (“Rennova” or the “Company”),
Read more
healthcare
GT Biopharma Receives Institutional Review Board Approval to Proceed With in Human FDA Phase 1 Clinical Trial
TAMPA, Florida, April 8, 2019 /CNW/ –GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology biotechnology company focused on innovative treatments based on
Read more
Todos and Amarantus Announce Completion of LymPro PET 1 Study by Leipzig University for Alzheimer’s Blood Diagnostic LymPro Test 2.0
REHOVOT, Israel and NEW YORK, April 08, 2019 (GLOBE NEWSWIRE) — Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics
Read more
BriaCell’s Lead Candidate Combined With KEYTRUDA®: Strong Evidence of Rapid Additive or Synergistic Anti-Tumor Activity
As presented at the American Association for Cancer Research (AACR) annual meeting: early efficacy data for the first six advanced
Read more
Interview: CEO Allen Davidoff of XORTX Therapeutics Inc.(OTCQB: XRTXF)
CEO Allen Davidoff of XORTX Therapeutics Inc., talks about their focus of developing therapies for kidney disease, diabetic nephropathy, and cardiovascular disease.
Read more
CytoDyn and Samsung BioLogics Enter into Agreement to Manufacture $1 Billion Worth of Leronlimab (PRO 140) to Meet Expected Demand for Future Revenues Post-Approval
VANCOUVER, Washington, April 02, 2019 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”) a late stage biotechnology company
Read more
Featured Interview: CEO Phillipe Deschamps of Helius Medical Technologies, Inc. (NASDAQ: HSDT)
Phillipe Deschamps of Helius Medical Technologies, Inc., discusses their PoNS technology, working with Health Canada, and possible timeline for receiving FDA results.
Read more
ProMIS Neurosciences to Present Data for Potential Best-in-Class Antibody Candidates for Parkinson’s Disease at AD/PD™ 2019 Conference
Canada NewsWire TORONTO and CAMBRIDGE, MA, March 19, 2019 Selected for podium presentation: novel antibody candidates bind only the toxic
Read more
CytoDyn Reaches Historical Milestone, Submits First of Three Sections of BLA to FDA for Leronlimab (PRO 140) as a Combination Therapy for HIV
VANCOUVER, Washington, March 18, 2019 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”) a late stage biotechnology company
Read more
Sunniva Launches First Three Cannabis Brands in California
VANCOUVER, BC / ACCESSWIRE / March 13, 2019 / Sunniva Inc. (“Sunniva”, the “Company”, “we”, “our” or “us”) (CSE: SNN)
Read more
Trident Brands Subsidiary Brain Armor® Announces Nationwide Distribution With CVS Pharmacy
Brookfield, WI, March 06, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Trident Brands Inc. (OTCQB: TDNT) today announced that their
Read more
FDA Grants Rolling Review for CytoDyn’s Planned BLA for Investigational HIV Therapy Leronlimab (PRO 140)
VANCOUVER, Washington, March 04, 2019 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), a late stage biotechnology company developing leronlimab (PRO 140),
Read more